整合FDG-PET/CT与MRI淋巴结分期在2018 FIGO分类中改善宫颈癌特定分期生存分层
该研究纳入2007至2016年丹麦欧登塞大学医院488例活检确诊宫颈癌患者,比较影像学淋巴结阳性与阴性者的疾病特异性死亡。结果显示影像学淋巴结阳性患者按FIGO-2018上调至IIIC期,且IB1-II期淋巴结阴性者死亡风险显著更低,支持因疑似淋巴结转移导致的分期迁移;但IIIC期内的精确预后价值受到挑战,未来FIGO分期修订可能纳入新的亚分期。
要点
- 488例宫颈癌患者中146例(30%)影像学淋巴结阳性,按FIGO-2018上调至IIIC期。
- IB1期5年累积死亡率淋巴结阴性0.8% vs 阳性7.1%(p=0.034)。
- IB2期0% vs 34.5%(p=0.003),II期15.1% vs 41.4%(p<0.0001),III期33.3% vs 46.6%(p=0.28)。
核心结论
- FIGO-2009 I-III期宫颈癌中三分之一女性影像学疑似淋巴结转移并按FIGO-2018上调至IIIC期。
- IB1-II期淋巴结阴性女性宫颈癌特异性死亡率显著低于淋巴结阳性女性,支持因疑似淋巴结转移导致的分期迁移。
- IIIC期内的精确预后价值受到挑战,未来FIGO分期修订可能纳入新的亚分期。
研究设计与样本
- 纳入2007至2016年丹麦欧登塞大学医院所有活检确诊宫颈癌患者,共488例按FIGO-2009进行临床分期。
- 在全身麻醉临床检查前进行FDG-PET/CT和MRI检查。
- 比较影像学淋巴结阳性与阴性女性的疾病特异性死亡率。
主要发现
- 影像学淋巴结阳性146例(30%):IA期0/36(0%),IB1期22/195(11%),IB2期14/30(47%),II期70/164(43%),III期40/63(63%)。
- IB1期5年累积宫颈癌死亡发生率淋巴结阴性0.8% vs 阳性7.1%(p=0.034)。
- IB2期0% vs 34.5%(p=0.003)。
- II期15.1% vs 41.4%(p<0.0001)。
- III期33.3% vs 46.6%(p=0.28)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Staging carcinoma of the uterine cervix (CCU) by FIGO-2018 suggests stage migration of FIGO-2009 stage I-III patients with lymph node metastasis into FIGO-2018 stage IIIC. We aimed to investigate the prognostic value of lymph node metastases identified by imaging. METHODS: We enrolled all patients with biopsy-verified CCU from 2007 to 2016 at Odense University Hospital, Denmark. FDG-PET/CT and MRI were performed before clinical examination in general anesthesia. Disease-specific mortality was compared between women with lymph node-positive and lymph node-negative imaging. RESULTS: In total, 488 patients underwent clinical staging according to FIGO-2009. Lymph node-positive imaging was identified in 146 (30%) patients: 0/36 (0%) in stage IA, 22/195 (11%) in IBI, 14/30 (47%) in IB2, 70/164 (43%) in II and 40/63 (63%) in III. The 5-year cumulative incidence of death due to CCU lymph node-negative vs. lymph node-positive patients was 0.8% vs. 7.1% (p = 0.034) in stage IBI, 0% vs. 34.5% (p = 0.003) in stage IB2, 15.1% vs. 41.4% (p < 0.0001) in stage II, and 33.3% vs. 46.6% (p = 0.28) in stage III by FIGO-2009. CONCLUSIONS: One of three women with FIGO-2009 stage I-III CCU had suspected lymph node metastasis on imaging and is upstaged to stage IIIC according to FIGO-2018. The cancer-specific mortality by CCU was significantly lower in the lymph node-negative women stages IBI-II, thus supporting stage migration due to suspected lymph node metastasis. However, the exact prognostic value within stage IIIC is challenged, and future revision of FIGO stages may include new sub-stages.
引用
- Holm J, Gerke O, Vilstrup MH, et al. Improved stratification of stage-specific survival for cervical uterine cancer by integrating FDG-PET/CT and MRI for lymph node staging in 2018 FIGO classification. Gynecol Oncol. 2022. PMID: 36182533. doi:10.1016/j.ygyno.2022.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。